Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2023

Genmab — Maj 2023

Planlagt Fastgjort Låst Flyttet Genmab
490 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #11

    Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
    05/03/23 -- TEPEZZA® (teprotumumab-trbw) Net Sales of $405.3 Million -- https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-first-quarter-2023-financial

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #12

      A bit low isn’t it?

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #13

        yes. time for Amgen to take over...

        1 Reply Last reply
        0
        • B Offline
          B Offline
          BioShare
          wrote on sidst redigeret af
          #14

          ...haha EL 🙂

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #15

            Jo, men: More recently, the Company has seen the expansion drive positive momentum in the business, including increases in new prescribers, patient enrollment forms and patient starts. As new prescribers and patients work through the reimbursement process, the Company expects a more meaningful impact to net sales later in the year.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #16

              Argenx states : initial two targets identified within immunology and cancer (in the collaboration with Genmab )

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #17

                Japan Grants Sakigake Designation to Lu AF82422 (Scheme for Rapid Authorization of Unapproved Drugs: accelerating the practical application of unapproved/off-label use of drugs for serious and life-threatening diseases )

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #18

                  Link Preview Image
                  Japan Grants Sakigake Designation to Satralizumab, Lu AF82422 | PHARMA JAPAN

                  The Ministry of Health, Labor and Welfare (MHLW) on March 24 granted sakigake designation to two API…

                  favicon

                  PHARMA JAPAN (pj.jiho.jp)

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bibob
                    wrote on sidst redigeret af
                    #19

                    God morgen fra Spanien. 🙂

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #20

                      God morgen, håber solen skinner på dig og markedet i dag bibob;-)

                      1 Reply Last reply
                      0
                      • A Offline
                        A Offline
                        AaBforever
                        wrote on sidst redigeret af
                        #21

                        Det går da meget godt i dag....minus Genmab.

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bibob
                          wrote on sidst redigeret af
                          #22

                          JKY. 08.20. Tak for det. 26 ˚ kl 09.00 er vel ok. 🙂 håber også markedet stiger i graderne i dag. 😉

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #23

                            new trial by the University of Birmingham (Genmab collaborates) in Relapsed Follicular Lymphoma, containing Epcoritamab + lenalidomide. Interesting how 2 of the experimental arms will open only in 2025 and 2027 with drugs still to be announced. https://clinicaltrials.gov/ct2/show/NCT05848765

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #24

                              Lyder dejligt bibob. Solen skinner også her og OMX +1,85%. Desværre kunne Genmab ikke følge helt med, men 0,59% har også ret;-)

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #25

                                Biontech conf call https://www.fool.com/earnings/call-transcripts/2023/05/08/biontech-se-bntx-q1-2023-earnings-call-transcript/ "in principle, FixVac could be an option for patients with advanced metastatic disease. But again, here, it's a question of the combination compounds. And this is something that is now in the focus of our upcoming studies evaluating the use of these vaccines in combination with our checkpoint immunomodulators, for example, the bispecific BNT312 and BNT311 molecules,
                                "

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #26

                                  https://labuonasalute.it/2023/05/08/tumori-del-sangue-3.html teclistamab in Italie now

                                  1 Reply Last reply
                                  0
                                  • troldmandenT Offline
                                    troldmandenT Offline
                                    troldmanden
                                    wrote on sidst redigeret af
                                    #27

                                    Ofte ser man biotech aktier stige frem mod mulig godkendelse. Genmab går i den anden retning. Nogen der ved om der er analytikere der hælder til et nej i denne omgang?

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #28

                                      Ja lidt underligt at der er nedtur frem mod regnskab i morgen og PDUFA date for epco

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #29

                                        Godt nok under lav omsætning

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #30

                                          Nogen der ved om FDA holder deres tidslinjer pt?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper